Siemens Healthineers Strategy 2025 to Focus on AI
By Labmedica International staff writers
Posted on 18 Jan 2018
Image: As part of its Strategy 2025, Siemens Healthineers plans to use data and AI to integrate existing and innovative technologies for therapy (Photo courtesy of iStock).
Siemens Healthineers (Erlangen, Germany) has laid out its strategy to bolster its market leadership by 2025 and beyond, aimed at accelerating profitable growth and delivering return. The company has stated that it is well prepared to take advantage of the paradigm shift and structural growth opportunities in healthcare.
Siemens Healthineers estimates its core markets to grow by 3-5% annually on average from 2016 to 2021 to more than €50 billion per year, driven by growing and aging population, rise in chronic diseases, and improved access to healthcare in the emerging markets. With healthcare productivity historically lagging behind that of the other industries, the industry is witnessing horizontal and vertical consolidation, and governments and insurers are changing the financial incentive systems to transform healthcare delivery from volume to value. Additionally, medicine is becoming more precise and accessible, thereby empowering patients.
Digitalization and the use of artificial intelligence is further driving these changes in healthcare. Big data is becoming a source of value creation in the sector due to its abundant availability. Siemens Healthineers believes that it is well positioned to capitalize on the opportunities being created in the market due to its strong market position across the continuum of care. The company aims to drive profitable growth in its core business further and has a roadmap to its improve future profitability. Siemens Healthineers' Strategy 2025 is focused specifically on five future-oriented areas:
• Utilizing its unique position in the in-vivo and in-vitro markets to combine data and knowledge around precision medicine and make it relevant for clinical use
• Using data and artificial intelligence to integrate existing and innovative technologies for therapy
• Coordinating and optimizing the patient journey through the healthcare continuum
• Developing a full range of technical, operational and clinical service offerings that are more effective and more efficient by using technologies from Siemens Healthineers
• Continuing to develop and invest in capabilities in artificial intelligence that support the above areas
Siemens AG is preparing to list Siemens Healthineers on the Prime Standard segment of the Frankfurt Stock Exchange's Regulated Market during the first half of calendar year 2018.
"It is a pleasure to talk about Siemens Healthineers, a business well prepared to take advantage of the paradigm shifts in healthcare," said Michael Sen. Chairman of the Supervisory Board of Siemens Healthineers and member of the Siemens Managing Board also responsible for the company's healthcare activities. "As a separate listed entity, Siemens Healthineers will have the entrepreneurial flexibility to actively shape its industry with a view to accelerating profitable growth and deliver return. It will also have direct access to the capital market, which will improve its ability to fund investment. Siemens will continue to actively support Siemens Healthineers as a majority shareholder."